International Delphi Consensus on the Management of AQP4-IgG+ NMOSD

Recommendations for Eculizumab, Inebilizumab, and Satralizumab

Friedemann Mann, MD, Romain Marignier, PhD, Jacqueline Palace, MD, PhD, Georgina Arrambide, MD, PhD, Nasrin Asgari, MD, PhD, DMSc, Jeffrey L. Bennett, MD, PhD, Bruce Anthony Campbell Cree, MD, PhD, MAS, Jérôme De Séze, MD, PhD, Kazuo Fujihara, MD, Ho Jin Kim, MD, PhD, Rebecca Hornby, PhD, Saif Huda, MD, DPhil, Najib Kissani, MD, Ingo Kletter, MD, Satoshi Kuwabara, MD, PhD, Marco Lana-Peixoto, MD, PhD, Lisa Law, MSc, M. Isabel Leite, MD, DPhil, Lekha Pandit, MD, PhD, Sean J. Pittcock, MD, Chao Quan, MD, PhD, Sudarshini Ramanathan, FRACP, PhD, Dalia Rotstein, MD, MPH, Albert Saiz, MD, PhD, Douglas Kazutoshi Sato, MD, PhD, and Adi Vaknin-Dembinsky, MD

Neural Neuroimmunol Neurolinfam 2023;10:e200124. doi:10.1212/NXI.00000000000200124

Abstract

Background and Objectives

Neuromyelitis optica spectrum disorder (NMOSD) is a rare debilitating autoimmune disease of the CNS. Three monoclonal antibodies were recently approved as maintenance therapies for aquaporin-4 immunoglobulin G (AQP4-IgG)–seropositive NMOSD (eculizumab, inebilizumab, and satralizumab), prompting the need to consider best practice therapeutic decision-making for this indication. Our objective was to develop validated statements for the management of AQP4-IgG–seropositive NMOSD, through an evidence-based Delphi consensus process, with a focus on recommendations for eculizumab, inebilizumab, and satralizumab.

Methods

We recruited an international panel of clinical experts in NMOSD and asked them to complete a questionnaire on NMOSD management. Panel members received a summary of evidence identified through a targeted literature review and provided free-text responses to the questionnaire based on both the data provided and their clinical experience. Responses were used to generate draft statements on NMOSD-related themes. Statements were voted on over a maximum of 3 rounds; participation in at least 1 of the first 2 rounds was mandatory. Panel members anonymously provided their level of agreement (6-point Likert scale) on each statement. Statements that failed to reach a predefined consensus threshold (≥67%) were revised based on feedback and then voted on in the next round. Final statements were those that met the consensus threshold (≥67%).

Correspondence

Dr. Paul
friedemann.paul@charite.de

From the Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité Universitatsmedizin Berlin, Germany; Hospices Civils de Lyon (R.M.), France; John Radcliffe Hospital (J.P.); Clinical Neurology-Oxford University (J.P.), Oxford, United Kingdom; Servei de Neurologia-Neurommunologista (G.A.), Centre de l’Esclerosi Multiple de Catalunya (Cemcat), Vall d’Hebron Institut de Recerca (G.A.), Vall d’Hebron Hospital Universitari, Universitat Autonoma de Barcelona (UAB), Spain; Departments of Regional Health Research and Molecular Medicine (N.A.), University of Southern Denmark, Odense, Denmark; Department of Neurology (N.A.), slagelse Hospital, Denmark; Programs in Neuroscience and Immunology (J.B.), Departments of Neurology and Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora; Department of Neurology (B.A.C.C.), UCSF Weill Institute for Neurosciences, University of California San Francisco; Department of Neurology (J.D.S.), Hôpitaux Universitaires de Strasbourg; INSERM U1119 Biopathologie de la Myéline (J.D.S.), Neuroprotection et Stratégies Thérapeutiques; Clinical Investigation Center (J.D.S.), Hôpitaux Universitaires de Strasbourg, France; Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine, and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Department of Neurology (H.J.K.), Research Institute and Hospital of National Cancer Center, Goyang, South Korea; Oxford PharmaGenesis Ltd (R.H., L.L.); Department of Neurology (S.H.), Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; Medical Research Center (N.K.), Marrakesh Medical School, Cadi Ayyad University; Neurology Research Institute and Hospital of National Cancer Center, Goyang, South Korea; Department of Neurology (I.K.), St. Josef Hospital, Ruhr Universitat Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungscentrum Kempfenhausen fur Multiple Sklerose Kranke, Berg, Germany; Department of Neurology (S.K.), Graduate School of Medicine, Chiba University, Japan; CIEM MS Research Center (M.L.-P.), Federal University of Minas Gerais, Belo Horizonte, Brazil; John Radcliffe Hospital (M.L.L.), University of Oxford, United Kingdom; KS Hegde Medical Academy Director (L.P.), Center for Advanced Neurological Research, Nitte University, Mangalore, India; Neurology (S.P.), Laboratory Medicine and Pathology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN; Department of Neurology and Rare Disease Center (C.Q.), National Center for Neurological Disorders, Huashan Hospital, Shanghai Medical College, Fudan University, China; Translational Neuroimmunology Group (S.R.), Kids Neuroscience Centre, and Brain and Mind Centre, Sydney Medical School, Faculty of Medicine and Health, University of Sydney; Department of Neurology (S.R.), Concord Hospital, Division of Neurology (D.R.), Department of Medicine, University of Toronto, Ontario, Canada; Neuroimmunology and Multiple Sclerosis Unit (A.S.), Service of Neurology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona, Spain; School of Medicine (D.K.S.), Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil; and Department of Laboratory and Neuroimmunology and The Agnes-Ginges Center for Neurogenetics (A.V.-D.), Hadassah-Medical Center, Ein-Kerem, Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Go to Neurology.org/NFN for all disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Neuromyelitis optica spectrum disorder (NMOSD) is a rare debilitating autoimmune disease of the CNS, characterized primarily by optic neuritis and longitudinal extensive transverse myelitis. It affects between 0.7 and 10 per 100,000 people, depending on geography and ethnicity, and is more common in women than men. NMOSD is recognized as a distinct disease from multiple sclerosis (MS), even though it may share similar clinical features, which can lead to misdiagnosis of NMOSD as MS. Patients with NMOSD experience long-term symptoms such as vision loss, weakness, sensory impairment, bladder and bowel dysfunction, neuropathic pain, and fatigue. Evidence suggests that 90% of patients with NMOSD will test seropositive for anti-aquaporin-4 immunoglobulin G (AQP4-IgG), a circulating pathogenic autoantibody and a key diagnostic biomarker for NMOSD.

Treatment of NMOSD involves the management of acute relapses, or attacks, and maintenance therapy to prevent further relapses. Before 2019, there were no approved therapies for AQP4-IgG–seropositive NMOSD; maintenance treatments, although empirically identified as being potentially beneficial in sustaining remission, were all off-label. These included rituximab, azathioprine, mycophenolate mofetil, methotrexate, tocilizumab, and oral corticosteroids. There are now 3 biologics approved as maintenance therapies specifically for adults, or adults/adolescents, with AQP4-IgG–seropositive NMOSD, in a range of countries: eculizumab, inebilizumab, and satralizumab. However, there are no standard treatment recommendations for AQP4-IgG–seropositive NMOSD that provide clear guidance on the use of these approved biologics or their role in the context of existing off-label maintenance therapies. Previous recommendations have focused only on the utilization of off-label therapies, or where new therapies were included, recommendations regarding their use are limited. As such, there is a clear and pressing need for new international recommendations for the management of AQP4-IgG–seropositive NMOSD.

Delphi consensus methods gather information from experts and allow for the development and validation of consensus statements that reflect the broad experience of key experts in a particular field. Consensus statements may inform clinical treatment guidelines in a therapeutic or disease area, especially for rare diseases, where standard practice recommendations may not yet be established or may not be updated on a regular basis.

We conducted an international Delphi process to generate and validate a series of evidence-based consensus statements for consideration in best practice therapeutic decision-making related to the use of eculizumab, inebilizumab, and satralizumab to treat patients with AQP4-IgG–seropositive NMOSD.

Methods

Overview

A modified Delphi consensus process was conducted, informed by a targeted literature review and clinical expertise. The Delphi panel comprised a steering committee of 3 members (one of whom was the nonvoting Chair of the panel). The steering committee have extensive expertise in NMOSD, especially for the newly approved therapies: they have been involved in the pivotal phase 3 trials for eculizumab, inebilizumab, and satralizumab. They also have broad knowledge of international, experienced clinicians in the field; thus, they were well placed to select the remaining panel members for this Delphi process. The steering committee selected panel members with 1 or more of the following credentials: they run specialized clinics for the treatment of...
AQP4-IgG–seropositive NMOSD; they lead national cohort studies to investigate outcomes of AQP4-IgG–seropositive NMOSD; they have knowledge of newly approved therapies for AQP4-IgG–seropositive NMOSD through involvement in the pivotal trials. In total, 21 additional panel members were selected, resulting in 24 participants overall, 23 of whom were voting members (Table 1). Countries represented by the panel include Australia (1 panel member), Brazil (2), Canada (1), China (1), Denmark (1), France (2), Germany (2), India (1), Israel (1), Japan (2), Morocco (1), South Korea (1), Spain (2), UK (3), and United States (3). After the targeted literature review (eAppendix 1, links.lww.com/NXI/A859), the Delphi consensus participants contributed to several stages: (1) information gathering to obtain expert opinion on topics related to NMOSD management; (2) generation of a list of draft statements related to NMOSD management; and (3) voting on the statements to confirm if expert consensus was reached (Figure).

**Proto-statement Questionnaire**

The initial information gathering stage was performed using a proto-statement questionnaire. This comprised a series of open questions capturing free-text responses from the Delphi panel to gain information and expert opinion on a range of key topics related to NMOSD management.

**Table 1** NMOSD Delphi Consensus Participants (n = 24) and Their Roles

<table>
<thead>
<tr>
<th>Participant (n)</th>
<th>Role/other details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair (1)</td>
<td>Responsible for agreeing the design of the Delphi consensus process, including selection of Delphi consensus panel members and the agreement threshold for statements questionnaire. Contributed to the development of the proto-statement questionnaire, initial statements, and revisions to statements that did not meet consensus. Did not participate in the voting stage of the Delphi process.</td>
</tr>
<tr>
<td>Steering committee member (3 including the chair)</td>
<td>Responsible for agreeing the design of the Delphi consensus process, including selection of Delphi consensus panel members, questionnaire and statement development, and the agreement threshold for statements questionnaire. Participated in the voting stage and/or questionnaire stage of the Delphi process.</td>
</tr>
<tr>
<td>Panel member (21)</td>
<td>Participated in the voting stage and/or questionnaire stage of the Delphi process. All Delphi panel members were identified based on their clinical expertise in the area of NMOSD and selected based on their willingness to participate and with an aim to create good representation for geographic location and gender.</td>
</tr>
<tr>
<td>Independent support</td>
<td>Support with consensus statement development and Delphi consensus voting rounds was provided by Oxford PharmaGenesis, Oxford, UK, an independent consultancy, which received funding from F. Hoffmann-La Roche Ltd.</td>
</tr>
</tbody>
</table>

Abbreviation: NMOSD = neuromyelitis optica spectrum disorder.

**Figure** Overview of NMOSD Delphi Consensus Process

NMOSD = neuromyelitis optica spectrum disorder.
topics in NMOSD management (eAppendix 2, links.lww.com/NXI/A859). To support this stage, panel members were provided with an evidence summary from the targeted literature review. Responses were collected securely online, through Google forms, and were extracted anonymously into an Excel spreadsheet.

**Generation of Statements**
Key themes were identified from responses to the proto-statement questionnaire. Within these themes, draft statements were developed using information from the responses.

**Voting Rounds**
The draft statements were voted on over a maximum of 3 rounds (Figure). As with the proto-statement questionnaire, responses in each round were collected through Google forms and were extracted anonymously into an Excel spreadsheet. Participation in at least 1 of the first 2 rounds was mandatory for each Delphi panel member. In round 1, panel members anonymously voted their level of agreement with each statement, using a 6-point Likert scale (strongly agree, agree, somewhat agree, somewhat disagree, disagree, and strongly disagree). If panel members selected 1 of the 3 responses that disagreed with the statement, they had the option to provide free-text feedback to explain their reasons for disagreement. Panel members were given no other instructions regarding how they should provide responses. In all voting rounds, the percentage agreement was compared with a predefined consensus threshold (≥67%) previously used in Delphi processes. Statements that failed to reach the predefined consensus threshold were revised based on feedback provided by those who disagreed with the statement. Revisions were approved by the steering committee (Table 1). In round 2, revised statements were voted on in the same way as in the first round. A third round took place if any of the revised statements still failed to meet the consensus threshold.

**Standard Protocol Approvals, Registrations, and Patient Consents**
Not required for this study.

**Data Availability**
All information and data pertaining to this study are included within this article. There is no further supplementary information that can be provided.

**Results**

**Overview**
Thirty-five articles were identified from the targeted literature review, including primary randomized controlled trial (RCT) data and review articles (eAppendix 3, links.lww.com/NXI/A859). Based on this evidence, and on feedback from the proto-statement questionnaire, 25 draft statements were developed.

**Voting Participation and Consensus**
All 23 voting members of the Delphi panel participated in at least 1 round of the process and thus qualified for membership of the final Delphi panel. In round 1, the participation rate was 78%, with 18/23 panel members voting on the 25 draft statements. After this voting round, 23 of the 25 statements reached consensus. Only 2 statements failed to reach consensus (levels of agreement were 61.1% and 66.7%); these statements were revised based on feedback. In round 2, 21/23 panel members (participation rate, 91.3%) voted on the revised statements. During this voting round, both statements reached consensus. A third voting round was therefore not required.

**Consensus Statements**

**Overall Results**
In total, the Delphi panel agreed on 25 consensus statements. The statements are summarized, by theme, in Tables 2–6 and are discussed individually in the next sections. Detailed voting responses are summarized in eTable 3 (links.lww.com/NXI/A859).

**Initiation of Eculizumab, Inebilizumab, or Satralizumab**
Nine consensus statements are relevant to the initiation of eculizumab, inebilizumab, or satralizumab (Table 2).

Statement 1 reached consensus in round 1 of voting (77.8% of panel agreed). The efficacy of eculizumab for the treatment of AQP4-IgG-seropositive NMOSD was demonstrated in an adult study population in the PREVENT trial. Approximately 211 weeks after randomization, the rate of adjudicated relapse was 3% in the eculizumab group and 43% in the placebo group (hazard ratio [HR] 0.06; 95% confidence interval [CI] 0.02–0.20; p < 0.001).

Statement 2 reached consensus in round 1 of voting (100% of panel agreed). The efficacy of inebilizumab for the treatment of AQP4-IgG-seropositive NMOSD was demonstrated in an adult study population in the N-MOmentum trial during a study period of up to 197 days. In the AQP4-IgG seropositive subgroup, the rate of attack, defined by prespecified attack criteria and adjudicated by committee, was 11% in the inebilizumab group and 42% in the placebo group (HR 0.227; 95% CI 0.121–0.423; p < 0.0001).

Statement 3 reached consensus in round 1 of voting (94.4% of panel agreed). Efficacy for satralizumab was demonstrated in adults and adolescents (≥12 years) in the SAkuraSky and SAkuraStar trials, during double-blind study periods of up to 224 weeks and 216 weeks, respectively. Among 55 patients in the SAkuraSky trial who were AQP4-IgG seropositive, the rate of protocol-defined relapse was 11% in those receiving satralizumab as add-on to baseline immunosuppressant therapy and 43% in those receiving placebo (HR [satralizumab vs placebo] 0.21; 95% CI 0.06–0.75). In SAkuraStar, among 64 patients in the trial who were AQP4-IgG seropositive, the rate of protocol-defined relapse was 22% in those receiving satralizumab as monotherapy and 57% in those receiving placebo (HR 0.26; 95% CI 0.11–0.63).
Table 2 NMOSD Delphi Consensus Statements on the Initiation of Eculizumab, Inebilizumab, or Satralizumab

<table>
<thead>
<tr>
<th>Consensus statement</th>
<th>Level of agreement, i.e., n/N (%)a panel members who agreed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statement 1: In adults with NMOSD who are AQP4-IgG seropositive, eculizumab may be initiated at diagnosis, after first attack or after relapse due to failure of existing treatments</td>
<td>14/18 (77.8%)</td>
</tr>
<tr>
<td>Statement 2: In adults with NMOSD who are AQP4-IgG seropositive, inebilizumab may be initiated at diagnosis, after first attack, or after relapse due to failure of existing treatments</td>
<td>18/18 (100%)</td>
</tr>
<tr>
<td>Statement 3: In adults and adolescents (12 y or older) with NMOSD who are AQP4-IgG seropositive, satralizumab may be initiated at diagnosis, after first attack, or after relapse due to failure of existing treatments</td>
<td>17/18 (94.4%)</td>
</tr>
<tr>
<td>Statement 4: The most important factors to inform decision-making for biologic NMOSD therapies are efficacy and safety</td>
<td>18/18 (100%)</td>
</tr>
<tr>
<td>Statement 5: In addition to efficacy and safety, current clinical disease activity and relapse severity, acceptability of the therapy's route of administration, and whether the therapy could be beneficial for overlapping comorbidities are all important factors that contribute to the selection of a biologic NMOSD therapy</td>
<td>18/18 (100%)</td>
</tr>
<tr>
<td>Statement 6: For newly diagnosed patients with AQP4-IgG seropositive NMOSD, the choice between eculizumab, inebilizumab, and satralizumab may be informed by patient preferences in dosing frequency, route of administration, and acceptance of potential safety risks, including during pregnancy</td>
<td>18/18 (100%)</td>
</tr>
<tr>
<td>Statement 7: When choosing between eculizumab, inebilizumab, and satralizumab for patients with NMOSD who are AQP4-IgG seropositive, an important consideration is the patient's response to prior maintenance therapy; clinicians should choose a therapy with an alternative mode of action to failed therapies</td>
<td>17/18 (94.4%)</td>
</tr>
<tr>
<td>Statement 8: While patients with AQP4-IgG seropositive NMOSD on off-label immunosuppressants (azathioprine, mycophenolate mofetil, and oral steroids) or off-label biologics (rituximab and tocilizumab) are currently free of relapse or tolerability issues, there is no need to initiate eculizumab, inebilizumab, or satralizumab</td>
<td>16/18 (88.9%)</td>
</tr>
<tr>
<td>Statement 9: There is evidence that patients with NMOSD who experience disease activity while treated with immunosuppressants and/or oral steroids would benefit from the addition of biologic therapies (eculizumab, inebilizumab, or satralizumab)</td>
<td>16/18 (88.9%)</td>
</tr>
</tbody>
</table>

Abbreviations: AQP4-IgG = anti-aquaporin-4 immunoglobulin G; GFAP = glial fibrillary acidic protein; N/A = not applicable; NfL = neurofilament light chain; NMOSD = neuromyelitis optica spectrum disorder.

* Threshold for consensus was ≥67%. Statements 1–9 achieved consensus during round 1.

Statement 4 reached consensus in round 1 of voting (100% of panel agreed). Efficacy and safety of treatment, as evidenced by RCT data, were the most common responses when panel members were asked to name the most important considerations when choosing therapies for patients with NMOSD. Other common responses were used to develop Statement 5.

Statement 5 reached consensus in round 1 of voting (100% of panel agreed). When panel members were asked to name the most important considerations for choosing therapies for patients with NMOSD, the most common responses after efficacy and safety of treatment were disease or relapse severity for the patient (mentioned by 47% of panel members); patient preference for treatment administration (47%); and comorbidities and other patient characteristics (24%).

Statement 6 reached consensus in round 1 of voting (100% of panel agreed). Based on the panel members’ clinical experience, the acceptance of safety risks by patients is an important factor in deciding their therapy. The panel members also agreed that patient preferences are highly relevant for choosing between eculizumab, inebilizumab, and satralizumab. The relevance is due to the differing administration route and schedule between treatments. Eculizumab is administered by IV infusion, every week during the initial phase and every 2 weeks during the maintenance phase. Inebilizumab is administered by IV infusion twice 2 weeks apart and once every 6 months. Satralizumab is administered by subcutaneous injection every 2 weeks during the initial phase and 4-weekly thereafter. Frequency and route of administration of treatments are known to influence patient preferences in other diseases.38 In NMOSD, the importance of patients’ preference was demonstrated in a US cross-sectional survey that found that 13% of patients with NMOSD were concerned about discomfort during administration, 11% were concerned about inconvenience of treatment, and 7% were concerned about impact on pregnancy decisions.39

Statement 7 reached consensus in round 1 of voting (94.4% of panel agreed). Panel members agreed that treatments with similar modes of action to a failed therapy are not likely to be effective. For example, satralizumab and tocilizumab are both interleukin-6 receptor targeting antibodies. Patients for whom tocilizumab therapy has failed may not experience positive outcomes with satralizumab. Furthermore, rituximab, an anti–cluster of differentiation (anti-CD) 20 monoclonal antibody,
and inebilizumab, an anti-CD19 monoclonal antibody, have similar mechanisms of action (although anti-CD19 therapy targets a wider range of B cells and some plasma cells compared with anti-CD20 treatments). Alternative modes of action, such as through eculizumab, which is a complement component 5 (C5) inhibitor, may be considered for such patients.

Statement 8 reached consensus in round 1 of voting (88.9% of panel agreed). Panel members agreed that patients who are relapse-free on their current therapy do not need to be switched to new therapies. Because the registration trials for the approved biologics (eculizumab, inebilizumab, and satralizumab) excluded nonrelapsing, clinically stable participants, there is no evidence to suggest that patients should switch to eculizumab, inebilizumab, or satralizumab if they are relapse-free on their current therapy. However, panel members acknowledged that the availability of long-term real-world data in the future may modify this recommendation, especially when data become available that allow comparison of the long-term safety profiles of eculizumab, inebilizumab, and satralizumab with those of conventional, off-label maintenance therapies (alone or with other treatments).

Statement 9 reached consensus in round 1 of voting (88.9% of panel agreed). Whereas statement 8 concerned patients with no disease activity on immunosuppressants, statement 9 concerns patients who do have disease activity. Evidence suggests that people on immunosuppressants need additional treatment to control disease activity. In a retrospective observational analysis, data in 116 patients with NMOSD who were treated with immunosuppressants (azathioprine or mycophenolate mofetil) showed that approximately one-third of patients responded poorly to treatment, especially if they had a history of severe attacks. This evidence suggests that, for some patients with NMOSD, conventional immunosuppressants alone, such as azathioprine and mycophenolate mofetil, are not sufficient to prevent attacks. At the same time, evidence suggests that discontinuation of conventional immunosuppressants may increase the risk of relapse for patients with AQP4-IgG–seropositive NMOSD, even after 5 years of remission. Thus, use of the newly approved biologics as add-on therapy may be justified. However, further evidence, particularly from RCTs, is needed to confirm the benefit of adding the approved biologic therapies to conventional immunosuppressants and to better characterize the risks of additional adverse events from dual immunotherapies.

Monotherapy vs Combination Therapy

Three consensus statements are relevant to the use of eculizumab, inebilizumab, or satralizumab as monotherapy or in combination with other therapies (Table 3).

Statement 10 reached consensus in round 1 of voting (88.3% of panel agreed). Whereas Statement 9 acknowledges that the combination of immunosuppressants with approved biologics could be beneficial, Statement 10 reflects the overall recommendation given the current evidence, which is to use biologics as monotherapy, where possible, because the use of combination therapy may be associated with a higher risk of infection.

The original version of Statement 11 failed to reach consensus during round 1 of voting, with the level of agreement falling below the predefined threshold of 67% (only 11/18 Delphi

### Table 3 NMOSD Delphi Consensus Statements on Monotherapy vs Combination Therapy and Switching Therapies

<table>
<thead>
<tr>
<th>Consensus statement</th>
<th>Level of agreement, i.e., n/N (%)a panel members who agreed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statement 10: Eculizumab, inebilizumab, or satralizumab should be given as monotherapy to patients with AQP4-IgG–seropositive NMOSD to reduce the risk of additional side effects of concomitant use with immunosuppressant therapies</td>
<td>15/18 (83.3%)</td>
</tr>
<tr>
<td>Statement 11: While monotherapy is preferred, evidence from randomized controlled trials shows that eculizumab or satralizumab may be combined with immunosuppressant therapies if the patient is already receiving immunosuppressants. Combination therapy should be considered in the context of the short-term and long-term safety and tolerability profiles of the immunosuppressants</td>
<td>18/21 (85.7%)</td>
</tr>
<tr>
<td>Statement 12: If eculizumab, inebilizumab, or satralizumab are initially combined with immunosuppressant therapy in patients with AQP4-IgG–seropositive NMOSD, patients should be closely monitored for side effects, and immunosuppressants should be slowly tapered, based on the expected onset of action of the new biologic therapy</td>
<td>17/18 (94.4%)</td>
</tr>
<tr>
<td>Statement 13: After initiation of eculizumab, inebilizumab, or satralizumab, and after allowing for onset of action, patients with AQP4-IgG–seropositive NMOSD should be switched to another of these 3 biologic therapies: if there is a severe relapse while on treatment; if serious treatment-related adverse events occur; or due to patient preference</td>
<td>16/18 (88.9%)</td>
</tr>
<tr>
<td>Statement 14: When switching between eculizumab, inebilizumab, and satralizumab, the new therapy can be started immediately after stopping the previous therapy, taking into consideration the mechanism and duration of action</td>
<td>18/21 (85.7%)</td>
</tr>
</tbody>
</table>

Abbreviations: AQP4-IgG = anti-aquaporin-4 immunoglobulin G; GFAP = glial fibrillary acidic protein; N/A = not applicable; NFL = neurofilament light chain; NMOSD = neuromyelitis optica spectrum disorder.

a Threshold for consensus was ≥67%. Statements 10, 12, and 13 achieved consensus during round 1; statements 11 and 14 achieved consensus during round 2, after revision.
Panel members agreed [61.1%]). After revision, 18/21 Delphi panel members (85.7%) agreed with the revised Statement 11 during round 2 of voting. The final Statement 11 builds on the recommendation in Statement 10, by acknowledging the scenario where clinicians may wish to maintain immunosuppressant therapy, for various reasons, for example, to treat a second autoimmune condition. The panel agreed that clinicians may do so. Maintaining immunosuppressant therapy is supported by findings from the SAkuraSky and PREVENT trials, which demonstrate that patients may continue receiving immunosuppressants with satralizumab and eculizumab, respectively, without major safety concerns.34,36 Immunosuppressant use continues to be supported by data from the open-label extension phases of these studies.36,43-45

Statement 12 reached consensus in round 1 of voting (94.4% of panel agreed). Many panel members raised concerns regarding the safety risks of combination therapy. The SAkuraSky and PREVENT trials assessed satralizumab and eculizumab, respectively, as an add-on therapy to immunosuppressants, and no major safety concerns were identified.34,36 However, further long-term evidence is needed. Without this evidence, panel members recommended tapering of immunosuppressants once biologic therapies are initiated.

**Switching Therapies**

Two consensus statements are relevant to switching between eculizumab, inebilizumab, and satralizumab (Table 3).

Statement 13 reached consensus in round 1 of voting (88.9% of panel agreed). Many panel members noted that the clinician should allow adequate time to observe the onset of action of the initial treatment, before considering switching to a new treatment. Regarding reasons for switching, severe relapse and adverse events were the most common responses indicated by the panel members. In addition, many noted that patient preference should always be taken into consideration.

The original version of Statement 14 failed to reach consensus during round 1 of voting. Panel members who disagreed had concerns regarding the initiation of a new treatment too soon after cessation of the previous treatment in case the lack of washout period led to strong immunosuppression in the patient. Panel members also recommended allowing sufficient time to observe the onset of action of the previous therapy. For example, pivotal RCTs for each of the biologics allowed a follow-up of 24–48 weeks to observe their primary end points. The revised version of the statement, which reached consensus in round 2 of voting, acknowledges that the mechanism and duration of action of the previous therapy should be considered. In total, 18/21 Delphi panel members (85.7%) agreed with the revised Statement 14 during round 2 of voting.

**Patient Populations**

Two consensus statements are related to considerations for different patient populations when using eculizumab, inebilizumab, or satralizumab (Table 4).

Statement 15 reached consensus in round 1 of voting (100% of panel agreed). Comorbidities were considered important in several ways. Long-term oral corticosteroid use can increase the risk of infection and can exacerbate preexisting conditions such as type 2 diabetes mellitus, osteoporosis, and glaucoma; thus, switching to eculizumab, inebilizumab, or satralizumab earlier may be appropriate. If a patient has more than 1 autoimmune disease, the condition with more significant disease activity should guide the treatment decision-making. However, specific treatments could complement the treatment of overlapping autoimmune disease; for example, satralizumab would be complementary for the treatment of rheumatoid arthritis, while eculizumab would be complementary for the treatment of myasthenia gravis.

Statement 16 reached consensus in round 1 of voting (88.9% of panel agreed). The efficacy of satralizumab was demonstrated in adults and adolescents (≥12 years) in the SAkuraSky trial, which supported the European Medicines Agency (EMA) approval for this indication.36 In the subgroup analysis of adolescents only, with NMOSD of any type, the safety profiles of the satralizumab add-on therapy and placebo treatment arms were comparable.50 It should be noted that this analysis was based on a small sample size of 8 patients, and it would be valuable to confirm this evidence in larger study.

---

**Table 4** NMOSD Delphi Consensus Statements on Patient Populations

<table>
<thead>
<tr>
<th>Consensus statement</th>
<th>Level of agreement, i.e., n/N (%) panel members who agreed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statement 15: Comorbidity in patients with NMOSD and concomitant autoimmune diseases should be a consideration in the choice of biologic therapy (eculizumab, inebilizumab, or satralizumab)</td>
<td>18/18 (100%)</td>
</tr>
<tr>
<td>Statement 16: Adolescents (12 year or older) with AQP4-IgG–seropositive NMOSD should be treated with satralizumab. Treatment with eculizumab or inebilizumab may be considered if there is severe disease activity that is refractory to satralizumab, but clinical trial evidence is needed to support the use of these drugs in other scenarios</td>
<td>16/18 (88.9%)</td>
</tr>
</tbody>
</table>

Abbreviations: AQP4-IgG = antiaquaporin-4 immunoglobulin G; NMOSD = neuromyelitis optica spectrum disorder.

*Threshold for consensus was ≥67%. Statements 15 and 16 achieved consensus during round 1.
populations. Data in adolescents are not currently available for eculizumab or inebilizumab.

**Safety**

Five consensus statements are related to the safety of eculizumab, inebilizumab, and satralizumab (Table 5).

Statement 17 reached consensus in round 1 of voting (100% of panel agreed). The Delphi panel members suggested that infections were the main safety concern to be monitored over time, particularly opportunistic infections, meningococcal meningitis, herpes zoster, and progressive multifocal leukoencephalopathy. The risk of these infections is emphasized in the EMA and US Food and Drug Administration (FDA) labels of eculizumab, inebilizumab and satralizumab. Moreover, monitoring individual patients reporting significant infections such as these to the manufacturer and other post-marketing databases (e.g., US FDA) would also be helpful in enabling wider monitoring of potential safety issues associated with these therapies.

Statement 18 reached consensus in round 1 of voting (83.3% of panel agreed). Patients with comorbidities that influence the risk of infection, adolescents, older people, pregnant women, and patients with significant immunosuppression were the most commonly mentioned subgroups when panel members were asked whether certain patient types should be monitored more closely than others.

Statement 19 reached consensus in round 1 of voting (100% of panel agreed). Many panel members noted that pregnancy and family planning is a key consideration for their patients. Current literature suggests that multidisciplinary teams should be involved in the overall treatment and care of pregnant women with NMOSD. Reviews of eculizumab treatment during pregnancy suggest there are no major safety concerns. Evidence is less clear for inebilizumab and satralizumab. A review of inebilizumab suggested that treatment could be linked to transient hematologic abnormalities in the fetus if given during the second or third trimester of pregnancy, in the same way as ocrelizumab or rituximab can lead to these abnormalities; however, this has not been formally investigated. Little evidence is available for satralizumab use during pregnancy. Potentially, evidence for tocilizumab use in rheumatoid arthritis during pregnancy could be indicative of satralizumab use, given the similarities between the 2 treatments for mechanism of action. Overall, recommendations in the literature emphasize that more evidence is needed for the newly approved NMOSD therapies during pregnancy and lactation, and a long-term follow-up of infants is also recommended. Plans to generate such evidence are under way: the US Food and Drug Administration mandated a worldwide single-arm pregnancy safety registry study to collect and analyze information for a minimum of 10 years on pregnancy complications and birth outcomes in women with NMOSD exposed to satralizumab and inebilizumab during pregnancy.

Statement 20 reached consensus in round 1 of voting (88.9% of panel agreed). In the PREVENT trial, all patients treated with eculizumab received the meningococcal vaccine, and there were no cases of meningococcal infection during the trial. Based on this clinical evidence, and their own experience, panel members agreed that all vaccinations, not only a meningococcal vaccine, should be up to date before treatment. This may include COVID-19 vaccination. It is not clear

<table>
<thead>
<tr>
<th>Consensus statement</th>
<th>Level of agreement, i.e., n/N (%)a panel members who agreed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statement 17: Patients with AQP4-IgG-seropositive NMOSD treated with eculizumab, inebilizumab, or satralizumab should be monitored in the short-term and long-term for infections</td>
<td>18/18 (100%)</td>
</tr>
<tr>
<td>Statement 18: Some patients with AQP4-IgG-seropositive NMOSD treated with eculizumab, inebilizumab, or satralizumab should be clinically monitored more frequently (more than twice per year); these include patients with comorbidities that influence the risk of infection, adolescents, older people, pregnant women, and patients with significant immunosuppression</td>
<td>15/18 (83.3%)</td>
</tr>
<tr>
<td>Statement 19: Available data regarding the use of eculizumab, inebilizumab, or satralizumab in patients with NMOSD during pregnancy are currently limited; further research is needed to gain a better understanding of the risk of complications in the short-term and long-term and will inform patient decision-making on family planning and treatment pathways</td>
<td>18/18 (100%)</td>
</tr>
<tr>
<td>Statement 20: Patients with NMOSD who are AQP4-IgG-seropositive should be up to date with all vaccinations before initiating new biologic therapies (eculizumab, inebilizumab, or satralizumab) unless there are exceptional circumstances</td>
<td>16/18 (88.9%)</td>
</tr>
<tr>
<td>Statement 21: Guidance concerning meningococcal vaccinations for patients treated with eculizumab should be clarified for patients with AQP4-IgG-seropositive NMOSD to ensure clinicians know how to cover all serogroups and when to schedule booster vaccinations and reassess vaccination status</td>
<td>17/18 (94.4%)</td>
</tr>
</tbody>
</table>

Abbreviations: AQP4-IgG = anti-aquaporin-4 immunoglobulin G; NMOSD = neuromyelitis optica spectrum disorder.

a Threshold for consensus was ≥67%. Statements 17–21 achieved consensus during round 1.
the extent to which new biologic therapies may interfere with vaccination efficacy, in a similar way to other therapies such as tocilizumab, anti-CD20 monoclonal antibodies, azathioprine, and mycophenolate mofetil.58-61 More evidence is needed to investigate potential interference with vaccine efficacy by eculizumab, inebilizumab, or satralizumab.

Statement 21 reached consensus in round 1 of voting (94.4% of panel agreed). The label for eculizumab typically contains recommendations on vaccinations required before treatment. For example, in the United States and EU, it is recommended that all patients on eculizumab receive the required meningococcal vaccines at least 2 weeks before initiating eculizumab (full details available in the treatment labels1,5,17). In some countries, for example, UK, antibiotic cover is also required.62 A previous review of eculizumab has called for clarification of the recommendations for vaccination in patients with NMOSD.63

Use of Biomarkers and Patient-Reported Outcomes

Three consensus statements are relevant to the use of biomarkers and patient-reported outcomes regarding treatment with eculizumab, inebilizumab, or satralizumab (Table 6). Statement 22 reached consensus in round 1 of voting (88.9% of panel agreed). Results from biomarker analyses of N-MOmentum trial data showed that elevated serum GFAP at baseline was significantly associated with a greater likelihood of NMOSD attack,64 and serum NfL level after an attack had a significant correlation with Expanded Disability Status Scale score.65 Panel members agreed that these biomarkers have the potential to be useful for predicting patient outcomes; however, more evidence is needed, especially for patients with NMOSD treated with satralizumab or eculizumab, for which there was no evidence related to biomarkers identified in the literature review.

Statement 23 reached consensus in round 1 of voting (88.9% of panel agreed). In results reported in their primary clinical trial publications, neither eculizumab nor satralizumab was associated with significant improvement in quality of life, although post hoc analyses of the PREVENT trial suggested a positive impact of eculizumab treatment on patients’ quality of life.66,67 The short duration of trials may have affected the primary results. Quality-of-life measures were not captured for inebilizumab in the N-MOmentum trial.

Statement 24 reached consensus in round 1 of voting (83.3% of panel agreed). In responses to the proto-statement questionnaire, some panel members doubted the reliability of current measures of quality of life, such as the 36-item Short-Form Health Survey and EuroQol 5-dimension 5-level (EQ-5D 5L), in a patient population with NMOSD. As such, panel members agreed that new, validated patient-reported outcome measures for NMOSD would be valuable for assessing the benefit of the newly approved biologic therapies.

Research Gaps

One consensus statement is relevant to current research gaps regarding the use of eculizumab, inebilizumab, and satralizumab (Table 6).

Statement 25 reached consensus in round 1 of voting (83.3% of panel agreed). This statement was based on responses to an item in the proto-statement questionnaire, which asked, “What are the most important research gaps in the current

---

Table 6 NMOSD Delphi Consensus Statements on the Use of Biomarkers and Patient-Reported Outcomes and Research Gaps

<table>
<thead>
<tr>
<th>Consensus statement</th>
<th>Level of agreement, i.e., n/N (%) panel members who agreed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statement 22: While serum glial fibrillary acidic protein (GFAP) and serum neurofilament light chain (NfL) have been shown to be markers of disease activity for NMOSD, more evidence is needed to support the routine use of biomarkers to support treatment decision-making in patients with AQP4-IgG-seropositive NMOSD</td>
<td>16/18 (88.9%)</td>
</tr>
<tr>
<td>Statement 23: Health-related quality-of-life outcomes in patients with AQP4-IgG-seropositive NMOSD are important to measure, but current evidence from clinical trials is not sufficient to influence therapy decision-making</td>
<td>16/18 (88.9%)</td>
</tr>
<tr>
<td>Statement 24: There is a strong need for sensitive, well-validated patient-reported outcomes that can be used to evaluate quality-of-life outcomes for NMOSD therapies</td>
<td>15/18 (83.3%)</td>
</tr>
<tr>
<td>Statement 25: Research priorities in the area of NMOSD are the investigation of the following: (1) prognostic biomarkers of relapse and disease progression; (2) predictive biomarkers to assess treatment response; (3) the role of imaging: (4) head-to-head evidence; and (5) long-term outcomes associated with the use of eculizumab, inebilizumab, and satralizumab, gathered through clinical trials and real-world data</td>
<td>15/18 (83.3%)</td>
</tr>
</tbody>
</table>

Abbreviations: AQP4-IgG = anti-aquaporin-4 immunoglobulin G; GFAP = glial fibrillary acidic protein; NfL = neurofilament light chain; NMOSD = neuromyelitis optica spectrum disorder.

* Threshold for consensus was ≥67%. Statements 22–25 achieved consensus during round 1.
evidence for newly approved therapies for NMOSD?” Among free-text responses from 17 panel members, the use of biomarkers and/or imaging was mentioned most frequently (by 7 panel members). Data on biomarkers, particularly for those that may be predictive of the risk of relapse or disease progression, were considered vital for informing treatment decisions, given the choice of biologics available. Such data would build on existing knowledge in this area, largely learned from the N-MOmentum trial (see statement 22). The supportive role of imaging has also been investigated in the N-MOmentum trial, and results showed that imaging was valuable in confirming relapses. It would also be beneficial to understand the impact of genetic variations on treatment response to allow individualized therapeutic decision-making; for example, in Japanese patients, a rare variant has been shown to affect treatment response to eculizumab. According to the panel, additional gaps included evidence related to the following: long-term efficacy and safety (mentioned by 5 panel members); head-to-head trials (5); children younger than 12 years (3); transitioning between therapies (2); first-line setting (1), predicting complications (1); and patients with low disease activity (1). One response also suggested there is a pressing need for a multinational NMO registry.

Discussion

An evidence-based modified Delphi consensus process was performed, which generated 25 validated statements to help inform therapeutic decision-making for patients with AQP4-IgG–seropositive NMSOD. The statements offer practical recommendations from experts related to the treatment of patients with AQP4-IgG–seropositive NMSOD with eculizumab, inebilizumab, or satralizumab.

The use of a geographically diverse panel of experts who were recruited to ensure perspectives were captured in a range of countries provides strength to the statements. The process combined expert experience with clinical evidence from published studies to generate and validate the consensus statements. A well-established Delphi method was used, with the consensus threshold decided a priori. Participation was mandatory in at least 1 voting round, but in this Delphi process, there was a high participation rate in all rounds.

The resulting statements are specific to AQP4-IgG–seropositive NMOSD, which is the only type of NMOSD indicated for the recently approved biologics. The finalized statements cover a broad range of topics in AQP4-IgG–seropositive NMOSD, many of which may have an immediate practical application for clinicians, such as the timing of initiation of biologic therapies, sequence of therapies (including when to switch), and potential long-term risks involved with biologics and immunotherapies for different subtypes of patient with NMOSD.

Although the wide geographic spread of the Delphi panel members is a strength of the process, it may also be considered a limitation, given that the level of clinical experience with the approved NMOSD therapeutics may vary between voting participants, depending on access to eculizumab, inebilizumab, and satralizumab in their region. Because the participants were not given specific instructions to vote on their agreement within the context of their experience only, or in an idealized setting, the impact of varying experience cannot be determined in the resulting statements. However, despite these factors, it should be noted that the level of agreement was high, with all but 1 statement obtaining more than 80% agreement and 11 statements obtaining more than 90% agreement. Another limitation of the statements is that the perspectives of nonclinical stakeholders, such as patients and payers, are not reflected. Throughout the Delphi process, the cost of treatments was considered not as important as efficacy and safety as a factor in decision-making. However, to patients and payers, especially in developing countries, cost is likely to be considered more important.

Consensus statements generated by a Delphi process can be a significant step toward standardizing care. The current statements aim to provide valuable guidance to clinicians, though it should be noted that some statements may be limited by a lack of specificity; for example, we were not able to state a precise length of time to monitor the duration of action of the therapies or confirm the best definition of severe relapse. In these cases, further development of statements was restricted by the amount of supporting evidence available. Despite these limitations, the NMOSD Delphi statements still address an unmet need in NMOSD treatment, for which the existing recommendations do not yet consider the most recently approved maintenance therapies. However, more research is needed to improve individualized treatment strategy further. The Delphi panel agreed that one of the key evidence gaps relates to the use of biomarkers that are predictive of treatment response; such biomarkers could allow for an optimized treatment strategy based on patient data. Comparative evidence between eculizumab, inebilizumab, and satralizumab and between these biologics and off-label therapies such as tocilizumab and rituximab would be valuable to inform decision-making between the available treatments. In the absence of head-to-head RCT data, comparative evidence may come from indirect treatment comparisons or from analysis of observational cohort data. Overall, continued monitoring of real-world data of eculizumab, inebilizumab, and satralizumab in patients with NMOSD is important in furthering our understanding of their long-term safety, tolerability, and efficacy profiles. Finally, given the importance of patient preferences, as highlighted throughout the statements, more insights into patient preferences for NMOSD treatment would be valuable to better understand the patient perspective and meet patients’ needs.

In conclusion, the consensus statements developed in this Delphi process seek to address an unmet need for providing recommendations on the use of eculizumab, inebilizumab, and satralizumab to treat patients with AQP4-IgG–seropositive NMOSD.
Acknowledgment
Oxford PharmaGenesis (Oxford, UK), an independent HealthScience communications consultancy, conducted the targeted literature review and provided support to draft the consensus statements. Lisa Law, MSc, and Rebecca Hornby, PhD of Oxford PharmaGenesis, Oxford, UK, are included as authors on this article for their contribution in drafting and editing the article and drafting responses to the reviewer comments. They are not members of the Delphi panel and did not vote in the consensus process. The authors also thank Jessica Townson of Oxford PharmaGenesis, Oxford, UK, for providing administrative and logistical support for the Delphi process. Funding for the Delphi process and medical writing support was provided by F. Hoffmann-La Roche Ltd. The funding organization did not contribute to the design, facilitation, or content of the Delphi consensus process.

Study Funding
F. Hoffmann-La Roche Ltd.

Disclosure
F. Paul served on the scientific advisory boards of Novartis and MedImmune; received travel funding and/or speaker honoraria from Bayer, Novartis, Biogen, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an associate editor of Neurology: Neuroimmunology & Neuroinflammation; is an academic editor of PLoS ONE; consulted for Sanofi Genzyme, Biogen, MedImmune, Shire, and Alexion; received research support from Bayer, Novartis, Biogen, Teva, Sanofi-Aventis/Gerzyme, Alexion, and Merck Serono; and received research support from the German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy-Jackson Charitable Foundation, and NMSS; J. Palace has received support for scientific meetings and honorariums for advisory work From Merck Serono, Novartis, Chugai, Alexion, Roche, MedImmune, Argenx, UCB, Mitsubishi, Amplo, Janssen, Sanofi. Grants from Alexion, Roche, MedImmune, UCB, and Amplo biotechnology; has patent ref P37347WO and licence agreement Numares multimarker MS diagnostics Shares in AstraZenica; and acknowledges partial funding by highly specialised services NHS England; R. Marignier reports personal fees from Viela Bio, Roche, and UCB and nonfinancial support from Viela Bio, Merck, Biogen, and Roche, outside the submitted work. AC-C reports funding from the Instituto de Salud Carlos III (Spain) JR19/00007; S. Ramanathan has received research funding from the National Health and Medical Research Council (Australia), the Petre Foundation, the Brain Foundation (Australia), the Royal Australasian College of Physicians, and the University of Sydney. She is supported by an NHMRC Investigator Grant (GNT2008339). She serves as a consultant on an advisory board for UCB and Limbic Neurology and has been an invited speaker for Biogen, Excemed, and Limbic Neurology; M. Lana-Peixoto reports no disclosures relevant to the manuscript; L. Law is an employee of Oxford PharmaGenesis; D.K. Sato reports grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, TEVA, and Merck and personal fees from TEVA, Merck, Biogen, Roche, and Viela Bio, outside the submitted work. KS reports personal fees from Biogen, Novartis, Merck, Roche, Celgene, and TG Therapeutics and grants from Merck and Roche, outside the submitted work; C. Quan received travel funding and/or speaker honoraria from Sanofi Genzyme, Novatis, Roche, Biogen, and Bristol Myers Squibb; is on the editorial board for Neuroimmunology Reports; and received research support from Novartis; N. Asgari reports no disclosures; J. De Seze has done some consulting and served on the board for Roche; I. Kleiter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Almirall, Biogen, Celgene, Hexal, Horizon, Merck, and Roche/Chugai; L. Pandit has received Speaker honorarium from Biogen and consulted for Biogen, Novartis, and Sanofi. She is listed as an inventor of a live cell-based assay for AQP4-IgG for which her university (Nitte university) holds a patent (No: 20214105841A); A. Vaknin-Dembinsky reported grants from F. Hoffmann-La Roche Ltd; personal fees from Roche, Biogen, Genzyme, Sanofi, Merck, and Novartis; and grants from Merck and the Ministry of Health of Israel outside the submitted work. No other disclosures were reported; K. Fujihara serves on scientific advisory boards or as a consultant for Biogen, Mitsubishi-Tanabe, Novartis, Chugai, Roche, Alexion, VielaBio/Horizon Therapeutics, UCB, Merck Biopharma, Japan Tobacco, Argenx, and Abbvie; has received funding for travel or speaker honoraria from Chugai, Roche, Biogen, Novartis, Alexion, Teijin, Mitsubishi-Tanabe, AsahKasei, Eisai, Takeda, and Bayer; serves on editorial boards of Clinical and Experimental Neuroimmunology, Frontiers in Neurology, Neurology: Neuroimmunology and Neuroinflammation, MS, MS and Related Disorders and Neuroimmunology Reports and advisory board of Sri Lanka journal of Neurology; and has been funded by the Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan and by the Grants-in-Aid for Scientific Research from the Ministry of Health, Welfare and Labor of Japan; S. Kuwabara reports no disclosures relevant to the manuscript; N. Kissani reports no disclosures relevant to the manuscript; H.J. Kim received a grant from the National Research Foundation of Korea and research support from Aprilbio and Eisai; received consultancy/speaker fees from Alexion, Aprilbio, Altos Biologics, Biogen, Celltrion, Daewoong, Eisai, GC Pharma, HanAll BioPharma, Handok, Horizon Therapeutics (formerly Viela Bio), Kolon Life Science, MDimmune, Mitsubishi Tanabe Pharma, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva-Handok, and UCB; is a coeditor for the MS Journal; and an associated editor for the Journal of Clinical Neurology; A. Saiz received compensation for consulting services and speaker honoraria from Merck, Biogen, Sanofi, Novartis, Roche, Janssen, Alexion, and Horizon Therapeutics; R. Hornby is an employee of Oxford PharmaGenesis; G. Arrambide has received speaking honoraria, compensation for consulting services, or
participation in advisory boards from Sanofi, Merck, Roche, and Horizon Therapeutics and travel support for scientific meetings from Novartis, Roche, and ECTRIMS; is the editor for Europe of the MS Journal—Experimental, Translational and Clinical, and is a member of the International Women in MS (iWiMS) Network executive committee and of the European Biomarkers in MS (BioMS-eu) Consortium steering committee; S. Huda reports no disclosures relevant to the manuscript; M.I. Leite is funded by the NHS (Myasthenia and Related Disorders Service and National Specialised Commissioning Group for Neuromyelitis Optica, UK) and by the University of Oxford, UK. She has been awarded research grants from the UK association for patients with myasthenia—Myaware and the University of Oxford. She has received speaker honoraria or travel grants from Biogen Idec, Novartis, UCB, and the Guthy-Jackson Charitable Foundation and serves on scientific or educational advisory boards for UCB Pharma, Argenx, and Viela/Horizon; J. Bennett has received grant support from Mallinckrodt Pharmaceuticals, Novartis, Alexion, NIH, and Guthy Jackson Charitable Foundation; received consulting fees from Alexion, Horizon Therapeutics, Reistone-Bio, Mitsubishi Tanabe, Sanofi-Genzyme, Antigenomycs, Beigene, Genentech-Roche, TG Therapeutics, and Chugai; and provides services on Independent Data Safety Monitoring Boards for Clene Nanomedicine and Roche. He provides editorial assistance to the Journal of Neuro-Ophthalmology, MS Journal, Neurology: Neuroimmunology & Neuroinflammation, and Frontiers in Ophthalmology. In the past 36 months, B. Cree has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Gossamer Bio, Horizon, Neuron23, Novartis, Sanofi, TG Therapeutics, and Therini and received research support from Genentech; D. Rotstein has received research support from the MS Society of Canada, Consortium of MS Centers (CMSC), University of Toronto Division of Neurology, and Roche Canada. She has received speaker’s or consultant’s fees from Alexion, Biogen, EMD Serono, Novartis, Roche, and Sanofi-Genzyme; S. Pittock has received personal compensation for serving as a consultant for Genentech, Sage Therapeutics, Astellas, and UCB. He’s received personal compensation for serving on scientific advisory boards or data safety monitoring boards for F. Hoffman-LaRoche AG, Genentech, and UCB. His institution has received compensation for serving as a consultant for Astellas, Alexion, and Viela Bio/MedImmune. All compensation is paid to Mayo Clinic. He has received research support from Alexion, Grifols, NIH, Viela Bio/MedImmune, F. Hoffman-LaRoche AG/Roche/Genentech, and NovelMed. All compensation is paid to Mayo Clinic. He has a patent, Patent# 8,889,102 (Application#12-678350, Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia)—issued; a patent, Patent# 9,891,219B2 (Application#12-573942, Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)–IgG Autoantibody positive)—issued; Patents for Kelch11, LUZP4, Septin, MAP1b Abs, GFAP-IgG, and PDE10A pending. Go to Neurology.org/NN for full disclosures.

**Publication History**

Received by Neurology: Neuroimmunology & Neuroinflammation August 17, 2022. Accepted in final form March 27, 2023. Submitted and externally peer reviewed. The handling editor was Editor Josep O. Dalmau, MD, PhD, FAAN.

---

**Appendix Authors**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friedemann Paul, MD</td>
<td>Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité Universitätsmedizin Berlin, Germany</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Chair and steering committee member. Reviewed and approved protocols for the targeted literature review and Delphi consensus process. Reviewed and approved draft versions of the proto-statement questionnaire and consensus statements. Did not participate in the voting stage of the Delphi process</td>
</tr>
<tr>
<td>Romain Marignier, PhD</td>
<td>Hospices Civils de Lyon, Service de Neurologie, Scérose en Plaques, Pathologies de la Myéline et Neuro Inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM), Hôpital Neurologique Pierre Wertheimer, Bron; Centre des Neurosciences de Lyon – FORGETTING team, INSERM 1028 et CNRS UMR5292; Université Claude Bernard Lyon 1, France</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: steering committee and Delphi panel member. Reviewed and approved protocols for the targeted literature review and Delphi consensus process. Reviewed and approved draft versions of the proto-statement questionnaire and consensus statements. Participated in the voting stage and/or questionnaire stage of the Delphi process</td>
</tr>
<tr>
<td>Jacqueline Palace, MD, PhD</td>
<td>John Radcliffe Hospital; Clinical Neurology Oxford University, United Kingdom</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: steering committee and Delphi panel member. Reviewed and approved protocols for the targeted literature review and Delphi consensus process. Reviewed and approved draft versions of the proto-statement questionnaire and consensus statements. Participated in the voting stage and/or questionnaire stage of the Delphi process</td>
</tr>
</tbody>
</table>
### Appendix (continued)

#### Name
- Georgina Arrambide, MD, PhD
- Nasrin Asgari, MD, PhD, DMSc
- Jeffrey L. Bennett, MD, PhD
- Bruce Anthony Campbell Cree, MD, PhD, MIAS
- jérôme De Séze, MD, PhD
- Kazuo Fujihara, MD
- Ho Jin Kim, MD, PhD
- Rebecca Hornby, PhD
- Saif Huda, MD, DPhil
- Najib Kissani, MD
- Ingo Kleiter, MD
- Satoshi Kuvabara, MD, PhD
- Marco Lanna-Peixoto, MD, PhD

#### Location
- Servei de Neurologia-Neuroenmunologia, Centre d'Esclerosi Multiple de Catalunya (Cemcat); Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari; Universitat Autònoma de Barcelona, Spain
- Departments of Regional Health Research and Molecular Medicine, University of Southern Denmark, Odense; Department of Neurology, Slagelse Hospital, Denmark
- Programs in Neuroscience and Immunology, Departments of Neurology and Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, CO
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, CA
- Department of Neurology, Hôpitaux Universitaires de Strasbourg; INSERM U1119 Biopathologie de la Myeline, Neuroprotection et Strategies Thérapeutique; Clinical Investigation Center, Hôpitaux Universitaires de Strasbourg, France
- Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan
- Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South Korea
- Oxford PharmaGenesis Ltd, United Kingdom
- Department of Neurology, Walton Centre NHS Foundation Trust, Liverpool, United Kingdom
- Medical Research Center, Marrakesh Medical School, Cadi Ayyad University; Neurology Department, University Teaching Hospital Mohammed VI, Marrakesh, Morocco
- Department of Neurology, St Joseph Hospital, Ruhr-University Bochum; Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhäuser für Multiple Sklerose Kranke, Berg, Germany
- Department of Neurology, Graduate School of Medicine, Chiba University, Japan
- CIEM MS Research Center, Federal University of Minas Gerais, Belo Horizonte, Brazil

#### Contribution
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process
- Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process

Continued
### Appendix (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Law, MSc</td>
<td>Oxford, PharmaGenesis Ltd, United Kingdom</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data</td>
</tr>
<tr>
<td>M. Isabel Leite, MD, MPhil</td>
<td>John Radcliffe Hospital, University of Oxford, United Kingdom</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process</td>
</tr>
<tr>
<td>Lekha Pandit, MD, PhD</td>
<td>KS Hegde Medical Academy Director, Center for Advanced Neurological Research, Nitte University, Mangalore, India</td>
<td>Drafting/revision of the manuscript for content; including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process</td>
</tr>
<tr>
<td>Sean J. Pittcock, MD</td>
<td>Neurology, Laboratory Medicine and Pathology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process</td>
</tr>
<tr>
<td>Chao Quan, MD, PhD</td>
<td>Department of Neurology and Rare Disease Center, National Center for Neurological Disorders, Huashan Hospital, Shanghai Medical College, Fudan University, China</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process</td>
</tr>
<tr>
<td>Sudarshini Ramanathan, FRACP, PhD</td>
<td>Translational Neuroimmunology Group, Kids Neuroscience Centre, and Brain and Mind Centre, Sydney Medical School, Faculty of Medicine and Health, University of Sydney; Department of Neurology, Concord Hospital, Sydney, Australia</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process</td>
</tr>
<tr>
<td>Dalia Rotstein, MD, MPH</td>
<td>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: Delphi panel member. Participated in the voting stage and/or questionnaire stage of the Delphi process</td>
</tr>
</tbody>
</table>

### References


International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
Friedemann Paul, Romain Marignier, Jacqueline Palace, et al.
Neurol Neuroimmunol Neuroinflamm 2023;10; DOI 10.1212/NXI.000000000000200124

This information is current as of May 31, 2023

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/10/4/e200124.full.html

References
This article cites 52 articles, 8 of which you can access for free at:
http://nn.neurology.org/content/10/4/e200124.full.html##ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Neuro-ophthalmology
http://nn.neurology.org/cgi/collection/all_neuroophthalmology
Optic nerve
http://nn.neurology.org/cgi/collection/optic_nerve
Optic neuritis; see Neuro-ophthalmology/Optic Nerve
http://nn.neurology.org/cgi/collection/optic_neuritis

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus